2022/08/06 更新

写真a

ワカマツ マナブ
若松 学
WAKAMATSU Manabu
所属
医学部附属病院 小児科 助教
大学院担当
大学院医学系研究科
職名
助教

学位 1

  1. 博士(医学) ( 2022年3月   名古屋大学 ) 

学歴 2

  1. 名古屋大学   医学系研究科   発育・加齢医学小児科学

    2018年4月 - 2022年3月

  2. 東北大学   医学部   医学科

    2006年4月 - 2012年3月

所属学協会 6

  1. 日本小児科学会

  2. 日本血液学会

  3. 日本造血・免疫細胞療法学会

  4. 日本小児血液・がん学会

  5. 日本免疫不全・自己炎症学会

  6. 日本輸血・細胞治療学会

▼全件表示

受賞 5

  1. 順清会 研究奨励賞

    2021年10月  

  2. 令和元年度名古屋大学医学系研究科 医学奨励賞

    2021年2月  

  3. 第277回日本小児科学会東海地方会 優秀演題賞

    2019年11月  

  4. 第55回中部日本小児科学会 特別賞

    2019年8月  

  5. 第10回JSH国際シンポジウム 優秀賞

    2019年5月  

 

論文 6

  1. TREC/KREC Newborn Screening followed by Next-Generation Sequencing for Severe Combined Immunodeficiency in Japan.

    Wakamatsu M, Kojima D, Muramatsu H, Okuno Y, Kataoka S, Nakamura F, Sakai Y, Tsuge I, Ito T, Ueda K, Saito A, Morihana E, Ito Y, Ohashi N, Tanaka M, Tanaka T, Kojima S, Nakajima Y, Ito T, Takahashi Y

    Journal of clinical immunology     2022年7月

     詳細を見る

    記述言語:英語  

    DOI: 10.1007/s10875-022-01335-0

    PubMed

  2. A patient with very early onset FH-deficient renal cell carcinoma diagnosed at age seven

    Taniguchi R., Muramatsu H., Okuno Y., Yoshida T., Wakamatsu M., Hamada M., Shirota C., Sumida W., Hinoki A., Tainaka T., Gotoh Y., Tsuzuki T., Tanaka Y., Kojima S., Uchida H., Takahashi Y.

    Familial Cancer   21 巻 ( 3 ) 頁: 337 - 341   2022年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:Familial Cancer  

    Hereditary leiomyomatosis and renal cell cancer (HLRCC) is caused by heterozygous germline variants in the fumarate hydratase (FH) gene and is associated with increased susceptibility to cutaneous leiomyomas, uterine leiomyomas, and renal cell carcinoma (RCC). HLRCC-associated RCC usually occurs in the middle age, with the median age being 40–44 years. This report describes a seven-year-old (84-month-old) male who developed a large right kidney tumor with multiple cystic lesions that contained enhanced solid components. There was no evidence of distant metastasis. The male patient underwent right nephrectomy and has been recovering well without metastasis or recurrence. Pathological examination revealed that tumor cells with relatively prominent nucleoli and surrounded by halos, were located in a limited area. Immunohistochemical staining was negative for FH. Whole-exome sequencing identified his germline variant in the FH gene and its loss of heterozygosity in the tumor. At nine years (114 months) of age, the male patient showed no recurrence of the tumor. This was the youngest-onset case of HLRCC-associated RCC to date. This report may affect the starting age for future RCC-surveillance programs for patients with HLRCC.

    DOI: 10.1007/s10689-021-00268-8

    Scopus

    PubMed

  3. Combination chemotherapy consisting of irinotecan, etoposide, and carboplatin for refractory or relapsed neuroblastoma

    Imaya Masayuki, Muramatsu Hideki, Narita Atsushi, Yamamori Ayako, Wakamatsu Manabu, Yoshida Taro, Miwata Shunsuke, Narita Kotaro, Ichikawa Daisuke, Hamada Motoharu, Nishikawa Eri, Kawashima Nozomu, Nishio Nobuhiro, Kojima Seiji, Takahashi Yoshiyuki

    CANCER MEDICINE   11 巻 ( 9 ) 頁: 1956 - 1964   2022年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:Cancer Medicine  

    Background: Patients with primary refractory and relapsed neuroblastoma have a poor prognosis since safe and effective chemotherapies for these patients are currently limited. The development of new chemotherapy regimens for these patients is imperative to improve survival outcomes. Methods: We retrospectively analyzed 40 patients with refractory (n = 36) or relapsed (n = 4) neuroblastoma who received irinotecan, etoposide, and carboplatin (IREC) as a second-line treatment. We evaluated their therapeutic response and the toxicity of IREC. We also assessed the impact of UGT1A1 gene polymorphisms, which are involved in irinotecan metabolism, on outcomes and toxicity. Results: A total of 112 cycles of IREC were administered to 40 patients with a median of 2 cycles per patient (range, 1–9). Six (15%) patients (UGT1A1 wild-type [n = 2] and heterozygous [n = 4]) showed objective responses, including partial response (n = 1), tumor shrinkage (n = 4), and improved findings on their MIBG scan (n = 1). Grade 4 neutropenia, grade 4 leukopenia, and grades 3–4 gastrointestinal toxicity were observed in 110 (98%), 88 (79%), and 3 (3%) cycles, respectively. There was no IREC-related mortality. Patients with UGT1A1 polymorphisms showed a higher frequency of grade 4 leukopenia, but these patients did not have increased treatment-related mortality or non-hematologic toxicity. Conclusions: IREC showed an objective response rate of 15% including 1 case with partial response. IREC was well tolerated regardless of UGT1A1 genotype. This study suggests that IREC is a promising second-line chemotherapy for refractory or relapsed neuroblastoma.

    DOI: 10.1002/cam4.4529

    Web of Science

    Scopus

    PubMed

  4. Minor PNH clones do not distinguish inherited bone marrow failure syndromes from immune-mediated aplastic anemia

    Narita Atsushi, Miwata Shunsuke, Imaya Masayuki, Tsumura Yusuke, Yamamori Ayako, Wakamatsu Manabu, Hamada Motoharu, Taniguchi Rieko, Okuno Yusuke, Muramatsu Hideki, Takahashi Yoshiyuki

    BLOOD ADVANCES   6 巻 ( 8 ) 頁: 2517 - 2519   2022年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:Blood Advances  

    DOI: 10.1182/bloodadvances.2021006044

    Web of Science

    Scopus

    PubMed

  5. A retrospective analysis of azacitidine treatment for juvenile myelomonocytic leukemia

    Honda Y., Muramatsu H., Nanjo Y., Hirabayashi S., Meguro T., Yoshida N., Kakuda H., Ozono S., Wakamatsu M., Moritake H., Yasui M., Sano H., Manabe A., Sakashita K.

    International Journal of Hematology   115 巻 ( 2 ) 頁: 263 - 268   2022年2月

     詳細を見る

    記述言語:日本語   出版者・発行元:International Journal of Hematology  

    Juvenile myelomonocytic leukemia (JMML) is a pediatric hematological malignancy with a poor prognosis. Although several case series have been published describing hematological and molecular responses to azacitidine (AZA) treatment in patients with JMML, the efficacy and safety profile of AZA is not well investigated, especially in Asian children and children undergoing hematopoietic stem cell transplantation (HSCT). We retrospectively analyzed 5 patients who received a total of 12 cycles (median 2 cycles) of AZA treatment in Japan. All five patients were boys and their ages at the time of treatment were 21, 23, 24, 26, and 46 months, respectively. All five patients tolerated AZA treatment, including four patients who received AZA after HSCT. Therapeutic toxicity with AZA was mostly limited to hematological toxicity. The only serious non-hematological adverse event was hyperbilirubinemia (grades III–IV) observed in a patient who received AZA after a second HSCT. Two out of five patients treated with AZA achieved a partial response (PR), while three patients treated for post-transplant relapse did not have an objective response. Future prospective studies should be conducted to develop combination therapies with AZA and other molecular targeted drugs for high-risk patients.

    DOI: 10.1007/s12185-021-03248-x

    Scopus

    PubMed

  6. Allogeneic stem cell transplantation with reduced intensity conditioning for patients with adrenoleukodystrophy 招待有り 査読有り

    MOLECULAR GENETICS AND METABOLISM REPORTS     2018年11月

     詳細を見る

    記述言語:英語  

▼全件表示

科研費 1

  1. 遺伝性骨髄不全症候群に対する網羅的プロテオミクス解析

    研究課題/研究課題番号:22K15601  2022年4月 - 2024年3月

    科学研究費助成事業  若手研究

    若松 学

      詳細を見る

    担当区分:研究代表者 

    配分額:4550000円 ( 直接経費:3500000円 、 間接経費:1050000円 )

    遺伝性骨髄不全症候群(Inherited Bone Marrow Failure Syndrome; IBMFS)は、貧血、血小板減少、顆粒球減少などの造血不全を合併する症候群である。多数の疾患を包括する概念であり、ファンコニ貧血、先天性角化不全症、シュワッハマン・ダイアモンド症候群などが含まれる。IBMFSには、遺伝子解析のみで診断が確定できない場合も多く、遺伝子解析を補完する技術として高深度プロテオーム解析を用いた、迅速かつ低コストの検査診断システムの構築を行う。